Gene or Genome – Page 8

Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results

4 months ago talkbio0Tagged Antibodies, Crohn 's disease, duvakitug, Gastrointestinal Diseases, Immunology, Inflammatory Bowel Diseases, Precision Medicine, TNFSF15 gene, Ulcerative Colitis

Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases

Merck Discontinues TIGIT and LAG-3 Programs Amid Efficacy Concerns

4 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Keytruda, lymphocyte-activation gene 3 protein, human, Merck, TIGIT gene

Merck, TIGIT, LAG-3, Keytruda, Cancer Therapy, Clinical Trials

FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns

4 months ago talkbio0Tagged Andexxa, Approved, AstraZeneca, concerns, F10 wt Allele, Hemorrhage, inhibitors, reversal agent, Safety, United States Food and Drug Administration

Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors

AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics

4 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, IL23R gene, Immunology, Inhibitor, Nimble, Peptides, Psoriasis

AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

4 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

ICER Report Highlights $815 Million in Unjustified Drug Price Increases in 2023

4 months ago talkbio0Tagged 2023, CREM gene, drug price, Health care facility, pharmaceutical costs, Report (document)

ICER report, unsupported drug price hikes, 2023, pharmaceutical costs, healthcare spending

Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

4 months ago talkbio0Tagged Affordable medication, CALR gene, Eli, Eli Lilly, Obesity, Pharmaceutical Services, Self-pay, single-dose, Telemedicine, Zepbound

Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

4 months ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor

uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130

5 months ago talkbio0Tagged Accelerated, AMT-130, Approved, cUHDRS, gene therapy, Huntington 's disease, NEFL gene, NfL, Regenerative Medicine, RMAT, UniQure, United States Food and Drug Administration

uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

5 months ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)